- LGM Pharma is investing an additional $9 million in its U.S. facilities, bringing total expansion investment to $15 million.
- The expansion will increase commercial manufacturing capacity and enhance R&D capabilities across Texas and Colorado sites.
LGM Pharma has announced a $9 million investment as part of the second phase of its CDMO growth strategy, expanding capabilities at its facilities in Rosenberg, Texas, and Colorado Springs, Colorado. The investment brings the company’s total recent expansion spend to $15 million, following a previously announced $6 million investment in 2025.
The expansion aims to increase commercial manufacturing capacity, strengthen research and development capabilities, and support growing demand for U.S.-based drug product manufacturing. The Rosenberg facility will receive $4 million to expand commercial-scale manufacturing suites for suppositories and enhance formulation and scale-up capabilities for solutions, suspensions, and semi-solid products.
In Colorado Springs, the company will invest $5 million to expand commercial manufacturing capacity for oral solid dose products, including orally disintegrating tablets. The site serves as LGM Pharma’s center of excellence for oral solid dose development, with the expansion expected to be completed this year.
The company stated that both facilities will remain operational throughout the expansion. LGM Pharma supports drug substance programs through a global network of more than 220 pre-qualified API manufacturers, while also expanding domestic drug product manufacturing to provide integrated support across the full product lifecycle under its contract manufacturing model.
“These multi-site investments totaling $15 million reflect our continued commitment to strengthening pharmaceutical supply chains in the United States.”
Prasad Raje, Chief Executive Officer of LGM Pharma
